DEF: Halozyme Therapeutics Sets Date for 2025 Annual Stockholders Meeting

Halozyme Therapeutics will hold its 2025 Annual Meeting of Stockholders online on May 1, 2025, to elect directors, vote on executive compensation, and ratify the selection of its accounting firm.

Summary

• Halozyme Therapeutics will hold its 2025 Annual Meeting of Stockholders online on May 1, 2025.
• Stockholders will vote to elect two Class III directors, approve executive compensation, and ratify the selection of Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors recommends voting FOR the director nominees and FOR Proposals 2 and 3.
• Only stockholders of record as of March 4, 2025, are entitled to vote.
• The company's Board of Directors consists of three classes, with directors serving three-year terms.
• The Board has determined that all directors, except Dr. Torley, are independent.
• The company has a corporate Enterprise Risk Management program reviewed quarterly by the CEO and leadership team, and annually by the Board.
• Halozyme continues to build a sustainable, environmentally conscious business.
• The company's cybersecurity strategy is based on policy, procedure, people, and technology.
• Stockholders can communicate with directors by mail.
• The Board has adopted a Code of Conduct and Ethics and Corporate Governance Guidelines, available on the company's website.
• The Compensation Committee has approved a Company-wide severance policy, outside of a change in control context, that is also applicable to our executive officers.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for shareholders to make informed decisions.

Positives

• The Board of Directors is comprised of individuals from diverse backgrounds.
• The company has a corporate Enterprise Risk Management program in place.
• Halozyme continues to build a sustainable, environmentally conscious business.
• The company has a well-defined and proven Business Continuity Plan (BCP).
• The company's insider trading policy requires compliance with all securities laws and regulations.
• The Board has adopted a Code of Conduct and Ethics and Corporate Governance Guidelines.
• The Compensation Committee has approved a Company-wide severance policy, outside of a change in control context, that is also applicable to our executive officers.

Risks

• The document mentions cybersecurity risks, which are overseen by the Audit Committee.
• The document mentions financial risks, which are overseen by the Audit Committee.
• The document mentions that the company's executive officers, directors, and principal stockholders, including their immediate family members and affiliates, are prohibited from entering into transactions which create, or would appear to create, a conflict of interest with us.

Future Outlook

At the Annual Meeting, we will review Halozymes activities over the past year and our plans for the future.

Management Comments

• It is important that you use this opportunity to take part in the affairs of Halozyme Therapeutics, Inc. by voting on the business to come before this meeting.
• Whether or not you plan to attend the Annual Meeting online, we hope you vote as soon as possible to assure your representation.
• The Board of Directors and management look forward to seeing you at the Annual Meeting.

Industry Context

This document is a standard proxy statement, which is a common requirement for publicly traded companies to inform shareholders and solicit votes on key corporate matters.

Comparison to Industry Standards

• The document mentions that the Compensation Committee annually selects a group of peer companies against which Halozyme benchmarks the competitiveness of executive pay levels and program design.
• The peer group companies are identified based upon the Compensation Committees assessment of each companys similarity with Halozyme with respect to science/business model, revenue, and market capitalization.
• The peer group is reviewed annually by the Compensation Committee.
• For 2024 compensation decisions, the Compensation Committee utilized proxy data from the following companies, listed below.
• The Compensation Committees objective in selecting this peer group was to include a group of similar-sized public companies in the life sciences sector, with an emphasis on pharmaceutical and biotechnology companies with commercialized products.
• Targeted companies generally had revenues and market capitalization between 0.25x to 4.0x Halozymes size at the time of the analysis with Halozyme near the median on both measures.
• The 2024 Peer Group includes: Acadia Pharmaceuticals, Alkermes, Alnylam Pharmaceuticals, Amicus Therapeutics, BeiGene, BioMarin Pharmaceutical, Blueprint Medicines, Exelixis, Insmed, Ionis Pharmaceuticals, Ironwood Pharmaceuticals, Ligand Pharmaceuticals, Neurocrine Biosciences, PTC Therapeutics, Sarepta Therapeutics, Ultragenyx Pharmaceuticals, and United Therapeutics.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders are provided with information to make informed decisions regarding director elections, executive compensation, and other corporate matters.
• Employees are subject to a Code of Conduct and Ethics.
• The company's sustainability efforts may impact customers and suppliers.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• Stockholders can attend the virtual Annual Meeting on May 1, 2025.

Key Dates